Immunovant IMVT
NASDAQ IMVT
$33.46 -0.03 (-0.09%)
At close: Sep 29, 2026 · 4:00 PM EDT

Immunovant (IMVT) Notes Payables (2018 - 2019)

Updated

Immunovant (IMVT) recorded Notes Payables of $300,000 in fiscal Q4 2019 (quarter ended Mar 31, 2019), unchanged from the prior quarter.

Analysis

Immunovant (IMVT) Notes Payables (2018 - 2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Immunovant 6.91 Bn 6.91 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 300,000.00
Dec 31, 2018 300,000.00
API Access

Immunovant Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=IMVT&period=max&api_key=YOUR_API_KEY